Table 1 Baseline demographic, clinical characteristics, and outcomes of the patients who developed acute respiratory distress syndrome (ARDS) SARS-CoV2-related and who have been enrolled in this study
Survivors (N = 4) | Non-survivors (N = 2) | Total (N = 6) | |
|---|---|---|---|
Age, years (mean ± SD) | 58.2 ± 13.9 | 71 ± 3.5 | 62.6 ± 12.9 |
Sex, N (%) | |||
Male | 3 | 2 | 5 (83.33%) |
Female | 1 | 0 | 1 (16.77%) |
Body mass index (median, range) | 28.5 (26.7–33.9) | 26.7 (25.8–27.7) | 27.8 (25.8–33.9) |
Charlson Comorbidity Index (median) | 2 | 3.5 | 3 |
Comorbidities, N (%) | |||
- Tabagic habit | 0 (0%) | 0 (0%) | 0 (0%) |
- Type 2 diabetes mellitus (T2DM) | 1 (25%) | 0 (0%) | 1 (16.66%) |
- Arterial hypertension (AH) | 2 (50%) | 0 (0%) | 2 (33.33%) |
- Chronic obstructive pulmonary disease (COPD) | 0 (0%) | 0 (0%) | 0 (0%) |
- Immunosuppression | 0 (0%) | 0 (0%) | 0 (0%) |
SOFA score (median) | 5.5 | 7 | 6.5 |
WHO ordinal scale score (median) | 4 | 4 | 4 |
PaO2/FiO2 ratio (mean ± SD) | 135 ± 36.9 | 89 ± 14.8 | 119.8 ± 37.6 |
Crs, cmH2O (mean ± SD) | 28.2 ± 4.7 | 27.5 ± 10.6 | 28 ± 6 |
Days in ICU (mean ± SD) | 58.7 ± 30.6 | 30.5 ± 0.7 | 49.3 ± 27.8 |
Days of mechanical ventilation (mean ± SD) | 28 ± 18.1 | 29.5 ± 0.7 | 28.5 ± 14.1 |
Steroid treatment, N (%) | 100% | 100% | 100% |
Antibiotic treatment, N (%) | 100% | 100% | 100% |
Antiviral treatment, N (%) | 0% | 0% | 0% |
Hyperimmune plasma treatment, N (%) | 75% | 50% | 66.66% |
WBC, 109/L (media ± SD) | 17.0 ± 10.3 | 20.2 ± 10 | 18.7 ± 9.2 |
Lymphocytes, 109/L (mean ± SD) | 4.2 ± 5.6 | 0.8 ± 0.2 | 3.1 ± 4.7 |
CRP, mg/dL (mean ± SD) | 6.55 ± 4.1 | 4.8 ± 6.7 | 5.9 ± 4.4 |
PCT, ng/mL (mean ± SD) | 0.3 ± 0.2 | 0.3 ± 0.0 | 0.3 ± 0.1 |
LDH, U/L (mean ± SD) | 670 ± 281 | 370 ± 117 | 570 ± 272 |